A randomized, double-blind, placebo-controlled, multicenter, parallel group, dose-response study to assess the efficacy and safety of topiramate in the treatment of patients with obesity
Phase of Trial: Phase II
Latest Information Update: 08 Dec 2010
At a glance
- Drugs Topiramate (Primary)
- Indications Obesity
- Focus Adverse reactions; Therapeutic Use
- Sponsors Janssen Research & Development
- 31 Aug 2018 Biomarkers information updated
- 14 May 2007 Status changed from in progress to completed.
- 18 Dec 2005 New trial record.